肿瘤药学2024，Vol.14Issue(4)：401-405,5.DOI:10.3969/j.issn.2095-1264.2024.04.03
1例维迪西妥单抗联合卡度尼利单抗治疗晚期膀胱癌致免疫相关性肝炎的病例分析
Analysis of a case of immune-related hepatitis caused by disitamab vedotin combined with cadonilimab in the treatment of advanced bladder cancer
郭一萌 1常可欣 2郝志英1
作者信息
- 1. 山西省肿瘤医院/中国医学科学院肿瘤医院山西医院/山西医科大学附属肿瘤医院 药学部,山西 太原,030013
- 2. 山西医科大学 药学院,山西 太原,030001
- 折叠
摘要
Abstract
Objective To analyze a case of immune-related hepatitis induced by the combination treatment of disitamab vedotin and cadonilimab,in order to provide references for the safe and rational clinical use of these drugs.Methods The clinical pharmacists analyzed the clinical manifestations,diagnostic and therapeutic approach,and treatment outcomes of a patient with advanced bladder cancer who developed immune-related hepatitis following treatment with disitamab vedotin and cadonilimab.Results After treatment with glucocorticoid,the patient's aminotransferase and bilirubin levels recovered,and the immune-related hepatitis grade dropped below grade 1.Conclusion The clinical manifestations of immune-related hepatitis are atypical,and it may be life-threatening if not treated in time.Physicians should promptly identify immune-relat-ed hepatitis based on clinical symptoms and relevant tests to implement early intervention and prevent severe adverse reac-tions.关键词
维迪西妥单抗/卡度尼利单抗/免疫相关性肝炎/药物性肝损伤Key words
Disitamab vedotin/Cadonilimab/Immune-related hepatitis/Drug-induced liver injury分类
医药卫生引用本文复制引用
郭一萌,常可欣,郝志英..1例维迪西妥单抗联合卡度尼利单抗治疗晚期膀胱癌致免疫相关性肝炎的病例分析[J].肿瘤药学,2024,14(4):401-405,5.
